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Objective: The study was undertaken to identify a monogenic cause of early onset, generalized dystonia.
Methods: Methods consisted of genome-wide linkage analysis, exome and Sanger sequencing, clinical neurological
examination, brain magnetic resonance imaging, and protein expression studies in skin fibroblasts from patients.
Results: We identified a heterozygous variant, c.388G>A, p.Gly130Arg, in the eukaryotic translation initiation factor
2 alpha kinase 2 (EIF2AK2) gene, segregating with early onset isolated generalized dystonia in 5 patients of a Taiwan-
ese family. EIF2AK2 sequencing in 191 unrelated patients with unexplained dystonia yielded 2 unrelated Caucasian
patients with an identical heterozygous c.388G>A, p.Gly130Arg variant, occurring de novo in one case, another patient
carrying a different heterozygous variant, c.413G>C, p.Gly138Ala, and one last patient, born from consanguineous
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parents, carrying a third, homozygous variant c.95A>C, p.Asn32Thr. These 3 missense variants are absent from
gnomAD, and are located in functional domains of the encoded protein. In 3 patients, additional neurological manifes-
tations were present, including intellectual disability and spasticity. EIF2AK2 encodes a kinase (protein kinase R [PKR])
that phosphorylates eukaryotic translation initiation factor 2 alpha (eIF2α), which orchestrates the cellular stress
response. Our expression studies showed abnormally enhanced activation of the cellular stress response, monitored by
PKR-mediated phosphorylation of eIF2α, in fibroblasts from patients with EIF2AK2 variants. Intriguingly, PKR can also
be regulated by PRKRA (protein interferon-inducible double-stranded RNA-dependent protein kinase activator A), the
product of another gene causing monogenic dystonia.
Interpretation: We identified EIF2AK2 variants implicated in early onset generalized dystonia, which can be dominantly
or recessively inherited, or occur de novo. Our findings provide direct evidence for a key role of a dysfunctional eIF2α
pathway in the pathogenesis of dystonia.
ANN NEUROL 2021;89:485–497
Pathogenic variants in various genes are known to causeinherited forms of dystonia.1,2 However, despite
recent progress in the identification of new causative genes
by next generation sequencing (NGS) methods, the
majority of patients are still etiologically unsolved,
suggesting that additional causative genes remain to be
identified. Eukaryotic translation initiation factor 2 alpha
kinase 2 (EIF2AK2), also known as protein kinase R
(PKR), is one of the 4 mammalian kinases involved in the
integrated cytoprotective reaction to stress conditions
(integrated stress response [ISR]).3 Canonical activation of
EIF2AK2 is mainly achieved by double-stranded RNA
(dsRNA) during viral infections.4 Subsequently, EIF2AK2
activates the ISR by phosphorylating eukaryotic transla-
tion initiation factor 2 subunit 1 (EIF2S1; also known as
eIF2α). The phosphorylation of EIF2S1 on the Ser51 resi-
due by EIF2AK2 prevents mRNA translation and results
in transient suppression of general protein synthesis, and
induction of cellular apoptosis.3 The activity of EIF2AK2
can also be regulated by the protein interferon-inducible
double-stranded RNA-dependent protein kinase activator
A (PRKRA; also known as PACT), in a dsRNA-
independent manner in response to cellular stress.5–7
Interestingly, biallelic pathogenic variants in the PRKRA
gene cause an autosomal recessive form of early onset gen-
eralized dystonia.8,9 Recent experimental evidence suggests
that in different inherited forms of dystonia, such as
DYT-TOR1A, DYT-THAP1, and DYT-PRKRA, the
molecular disease mechanisms converge toward disturbed
eIF2α pathway signaling.10–12 Moreover, rare variants in
the ATF4 gene (coding for the downstream effector of
eIF2α) have been reported in patients with cervical dysto-
nia.11 However, a direct genetic involvement of key com-
ponents of this pathway in dystonia have remained elusive
so far. Very recently, de novo EIF2AK1 and EIF2AK2
missense variants were reported in children with develop-
mental delay, leukoencephalopathy, and neurologic regres-
sion following febrile illness, with varying combinations of
neurological manifestations, including dystonic features in
some.13 Here, we report the identification of EIF2AK2
variants implicated in the development of early onset gen-
eralized dystonia, with or without additional neurological
disturbances, and inherited as an autosomal dominant or
autosomal recessive trait, or occurring de novo.
Subjects and Methods
Patients
The study was approved by the ethical authorities at the partici-
pating institutions, and written informed consent was obtained
for each participant. Initially, a Chinese Han family from Taiwan
with 5 members in 2 consecutive generations affected by early
onset, isolated, generalized dystonia (Family A; Fig 1A) was iden-
tified. Subsequently, 2 independent series of unrelated patients
with early onset dystonia and with whole exome sequencing
(WES) data available (n = 50, Centogene, Germany; n = 45,
Besta Institute, Italy) were studied. Finally, in 96 unrelated
patients with early onset or familial generalized dystonia collected
in Lübeck, Germany, the entire coding region and exon–intron
boundaries of EIF2AK2 (NM_002759.3) were sequenced by
Sanger methods.
Furthermore, from 3 patients carrying EIF2AK2 variants
(A-III-4, B-II-1, E-II-3), skin biopsies were collected and fibro-
blast cell cultures established for protein expression studies.
Fibroblast cell cultures from 3 neurologically normal anonymous
donors were used as controls.
Genetic Studies: Family A
Genomic DNA of participating individuals was extracted from
peripheral blood using standard protocols. Additionally, in
2 patients (A-III-1 and A-III-3) mRNA was also isolated and
cDNA synthesized using standard protocols. Standard karyotype
studies on peripheral blood, and screening of known genes caus-
ing dystonia were negative. High-density genome-wide
genotyping was performed with the Infinium OmniExpress 12v1
Kit (Illumina, San Diego, CA), and genome-wide copy number
variant (CNV) analysis was carried out with Nexus Copy Num-
ber (v10, BioDiscovery, El Segundo, CA). Although the pedigree
was not large enough to yield genome-wide significant evidence
for linkage, we performed linkage analyses to generate a catalog
of genomic regions of interest (regions with logarithm of odds
[LOD] score > 0) for filtering of WES variants. Multipoint para-
metric affected-only linkage analysis was performed with
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FIGURE 1: Pedigrees and genetic analyses. (A–E) Pedigrees of the patients with EIF2AK2 variants. Subjects with DNA available
are labeled with individual codes; filled symbols denote individuals affected with generalized dystonia; half-filled symbol
indicates right arm and hand dystonia; top-right quarter-filled symbol indicates history of mild foot dystonia and asymptomatic
upon examination; top-left quarter-filled symbol indicates mild bilateral hand tremor; M/M, homozygous carrier of denoted
variant; M/−, heterozygous carrier; −/−, wild-type. (F) Autosomal dominant and X-linked linkage analysis plots. LOD = logarithm
of odds. (G) Linkage analysis plot for chromosome 2 and location of the EIF2AK2 gene. (H) Schematic representation of the
EIF2AK2 protein, with functional domains and the relative positions of variants identified in this study. [Color figure can be
viewed at www.annalsofneurology.org]
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MERLIN14 under autosomal dominant, autosomal recessive, and
X-linked dominant or recessive modes of inheritance. In the
index case, the exome was captured using Illumina’s TruSeq
Exome Kit and sequenced with a HiSeq2000 instrument. The
reads were aligned to the genome build GRCh37/hg19 with the
Burrows–Wheeler Aligner15 and further processed with Genome
Analysis Toolkit Best Practices.16 Using the exome data, we first
searched for variants in genes associated with dystonia. We then
searched for variants located within the regions of interest
resulting from our linkage analysis. Variants were filtered
according to (1) location within linkage regions with LOD > 0;
(2) minor allele frequency (MAF) < 0.01% in any public data-
base (dbSNP, ExAC, ESP6500, 1000 Genomes, and gnomAD),
as well as in the subpopulation dataset East-Asia within
gnomAD; (3a) exonic nonsynonymous; or (3b) location within
±4 bases from exon–intron boundaries. Retained variants were
validated by Sanger sequencing and analyzed for segregation with
disease in Family A. In Patients A-III-1 and A-III-3, we also per-
formed cDNA analysis of EIF2AK2 (protocols and results are
available on request).
Additional Genetic Studies
To identify additional patients with EIF2AK2 variants, we con-
sulted 2 independent NGS databases: (1) the Centogene data-
base (Rostock, Germany), containing 50 unrelated patients with
early onset isolated forms of generalized dystonia; and (2) the
Besta Institute cohort (Milan, Italy), containing 45 unrelated
patients with genetically unexplained early onset dystonic
disorders.
For samples in the Centogene database, DNA was
extracted from ethylenediaminetetraacetic acid (EDTA) blood or
from dried blood spots in filter cards (CentoCard) using standard
methods. Exome or whole genome sequencing (WGS) was previ-
ously performed for diagnostic purposes. For WES, the Sur-
eSelect Human All Exon kit (Agilent, Santa Clara, CA) was used
for enrichment, then the exome was sequenced using a
HiSeq4000 (Illumina) sequencer, with an average coverage
targeted to 100x. For WGS, genomic DNA was fragmented by
sonication and Illumina adapters ligated for subsequent sequenc-
ing on the HiSeqX platform (Illumina) at average coverage depth
of 30x. CNV calling is based on the HiSeq Analysis Software’s
pipeline. Variants were annotated using ANNOVAR17 and in-
house bioinformatics tools,18 including CentoFit for prioritiza-
tion. Samples recruited at the Besta Institute were sequenced at
Northwestern University, Chicago, Illinois. Exomes were cap-
tured using Illumina’s Nextera Rapid Capture according to the
manufacturer’s recommendations. Indexed and pooled libraries
were then sequenced on Illumina’s HiSeq3000 (100 base pairs,
paired-end). Bioinformatic analysis of WES data was performed
as previously described.19
In all identified EIF2AK2 variant carriers, variants in other
genes associated with dystonia were not found. The EIF2AK2
variants identified by NGS were confirmed using Sanger
sequencing (protocols and primers are available upon request).
When DNA was available, parents were also tested for the
EIF2AK2 variant present in their offspring by Sanger methods.
Cell Culture
Fibroblast cell cultures were expanded in growth medium
(Dulbecco modified Eagle medium, 15% fetal calf serum). The
day before treatment, fibroblasts were plated at 150,000 cells/well
of a 6-well plate and incubated overnight in growth medium.
The next day, cell cultures were transfected with either 2μg/ml
(final concentration) polyinosinic acid:polycytidylic acid (poly[I:C])
high molecular weight (HMW) (tlrl-pic, InvivoGen, San Diego,
CA) using Viromer Red transfection reagent (TT100302,
OriGene, Rockville, MD) or Viromer Red only (untreated con-
trol cell cultures) according to the manufacturers’ specifications,
and incubated for indicated times at 37C/5% CO2.
Western Blotting
Western blotting analyses were performed as described previ-
ously.20,21 Validated primary antibodies used were rabbit anti–
phospho-eIF2α (Ser51; 119A11; CST, 3597), mouse anti-eIF2α
(sc-133132, Santa Cruz Biotechnology, Santa Cruz, CA), mouse
anti-EIF2AK2 (MAB1980-SP, R&D Systems, Minneapolis,
MN), rabbit recombinant anti-EIF2AK2 (phospho-Thr446)
antibody (E120, AB32036, Abcam, Cambridge, MA), and
mouse anti-Vinculin (sc-377103, Santa Cruz Biotechnology).
Secondary antibodies used were fluorescently conjugated goat
anti-mouse (IRDye 800) and goat anti-rabbit (IRDye 680) anti-
bodies (LI-COR Biosciences, Lincoln, NE) incubated simulta-
neously. Blots were imaged and analyzed using an Odyssey
imaging system (LI-COR Biosciences).
Statistical Analysis
Two-way analysis of variance with Tukey multiple comparisons
test was performed using Prism version 8.0.0 for Windows
(GraphPad Software, San Diego, CA), comparing subjects with
EIF2AK2 variants and controls. Values represent
mean ± standard error (n = 3 biological replicates).
Results
Family A
WES (Patient A-III-3) reached an average coverage of 92x
of target regions. Variants of interest were not found in
known genes causing dystonia. The linkage analysis under
an autosomal recessive inheritance model yielded only one
region with LOD score > 0 (heterogeneity LOD = 0.968;
hg19, chr20:18,152,134–18,967,523); however, WES
variants were not found therein. With X-linked dominant
or recessive models, no LOD > 0 regions were obtained.
Lastly, the autosomal dominant linkage model yielded
36 genomic regions with LOD > 0 (see Fig 1F), which
contained 8 WES variants of interest according to our
criteria. After validation by Sanger sequencing,
cosegregation analysis left only one variant, c.388G>A, p.
Gly130Arg, in heterozygous state in the EIF2AK2 gene,
segregating with the disease in Family A. This variant is
absent in all population databases, but is predicted as
benign by most in silico tools. Furthermore, because the
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variant is located 2 nucleotides away from an exon–intron
boundary, we performed cDNA studies in 2 patients,
A-III-1 and A-III-3, and found no evidence of aberrant
EIF2AK2 mRNA splicing (data not shown). Considering
the extreme rarity of the p.Gly130Arg missense variant,
the rarity of coding variants throughout the entire open
reading frame (ORF) of this gene in human databases, the
lack of other WES variants of interest, and the known
functional links between the proteins encoded by
EIF2AK2 and PRKRA (causing DYT-PRKRA), we consid-
ered EIF2AK2 as the candidate disease-causing gene in
Family A.
Additional EIF2AK2 Families
Searching the Centogene WES/WGS databases yielded a
total of 3 unrelated probands (B-II-1, C-II-1, D-II-1) with
early onset generalized dystonia carrying heterozygous
EIF2AK2 missense variants, all absent from gnomAD and
other public databases (Table 1). Of note, 2 of these pro-
bands carried the same variant as the patients in Family A
(c.388G>A,p.Gly130Arg); the first is a German patient of
Caucasian origin (B-II-1), who inherited the variant from
his asymptomatic and neurologically normal father
(Family B; see Fig 1B); the other is a boy from Canada
with French–Dutch ancestry (C-II-1, Family C; see
Fig 1C). After testing both his parents by Sanger sequenc-
ing for the variant, and for microsatellite markers to con-
firm paternity, we established the c.388G>A, p.
Gly130Arg variant as occurring de novo. Furthermore,
one additional Israeli patient of Ashkenazi Jewish and
Moroccan origin (D-II-1) carried a different heterozygous
EIF2AK2 missense variant: c.413G>C, p.Gly138Ala
(Family D; see Fig 1D), which was also found in his
mother.
In the Besta Institute cohort, one Italian patient
(E-II-3) was identified with early onset generalized
dystonia who carried a third EIF2AK2 missense variant,
c.95A>C, p.Asn32Thr, in homozygous state (Family E;
see Fig 1E). The variant, also absent from gnomAD and
all public databases (see Table 1), was detected in hetero-
zygous state in both parents and in one sibling, all asymp-
tomatic and neurologically normal. The parents are
consanguineous. Last, Sanger sequencing of the entire
EIF2AK2 ORF in the additional 96 dystonia patients
from Lübeck detected no further variants with MAF
< 1% in gnomAD.
The clinical features in the patients with EIF2AK2
variants identified in this study are reported in Table 2,
and videotapes of 5 Taiwanese, the Canadian, and the
Italian patient are available (Supplementary Videos).
Shared, prominent clinical characteristics include dystonia
with onset in infancy or childhood, with subsequent gen-
eralization. The anatomical location of the dystonia at
onset varied, from the upper to lower extremities. Differ-
ent patients displayed severe involvement of the axial mus-
cle with dystonic overextension of the back and neck
(retrocollis), reminiscent of axial dystonia in DYT-
PRKRA,9 and neurodegeneration with brain iron accumu-
lation syndromes.22 Additional neurological or other clini-
cal manifestations were absent in the 5 Taiwanese patients
and the German patient, who carried the p.Gly130Arg
variant. Their brain magnetic resonance imaging (MRI)
scans were unremarkable. Conversely, the Canadian
patient with a de novo p.Gly130Arg variant, and the
Israeli and the Italian case with different missense variants,
displayed prominent, generalized dystonia of early onset,
but also varying degrees of additional neurological mani-
festations and MRI features. These patients are therefore
described in more detail.
In the Canadian patient (C-II-1, Family C; see
Fig 1C), family and perinatal history were unremarkable.
Bilateral hand tremor was noted at the age of 3.5 years,












A 2:37368697 c.388G>A p.Gly130Arg 7 Absent Heterozygous
B 2:37368697 c.388G>A p.Gly130Arg 1 Absent Heterozygous
C 2:37368697 c.388G>A p.Gly130Arg 1 Absent Heterozygous, de
novo
D 2:37366877 c.413G>C p.Gly138Ala 2 Absent Heterozygous
E 2:37374855 c.95A>C p.Asn32Thr 1 Absent Homozygous
Variants are annotated according to genome build GRCh37/hg19 and EIF2AK2 transcript NM_002759.
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A-II-3 M/Han
Taiwanese
p.Gly130Arg 18/49 Trunk Trunk, legs 78 None T, D, B, C nd
A-III-1 F/Han
Taiwanese
p.Gly130Arg 10/25 Left toe, leg Trunk, limbs 50 None T, D, B, C +
A-III-2 M/Han
Taiwanese
p.Gly130Arg 5/24 Legs, hands Trunk, limbs,
larynx





p.Gly130Arg 4/21 Trunk, limbs Trunk, limbs,
larynx























































B, L, Bot nd
Variants are annotated according to genome build GRCh37/hg19 and EIF2AK2 transcript NM_00275.
AAE = age at examination; AAO = age at onset; B = baclofen; BFMS = Burke–Fahn–Marsden Dystonia Rating Scale; Bot = botulinum toxin;
C = clonazepam; D = diazepam; DBS = deep brain stimulation surgery performed; F = female; ID = intellectual disability; L = L-dopa; M = male;
MRI = magnetic resonance imaging; na = not applicable; nd = not performed; nk = not known; other1 = carisoprodol, carbamazepine, and clozapine;
other2 = carbamazepine; other3 = tetrabenazine; T = trihexyphenidyl.
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followed by abnormal posturing (inversion) of his left
foot. The dystonic posturing worsened and spread to the
ipsilateral arm by the age of 4 years, and to the right body
side by 4.5 years, more severe in the leg than the arm, and
exacerbated with movement. Mild proximal weakness in
the lower extremities and dysarthria were also apparent.
When the patient was 5 years old, the dystonia had
become generalized, with fluctuating severity. He had fre-
quent falls and difficulty with fine motor skills, due to the
tremor and dystonia, and often required a wheelchair to
move across longer distances. Interestingly, periodic, step-
wise deterioration in his dystonia occurred following cer-
tain viral infections and/or surgical interventions. At the
age of 5.5 years, following an elective hospitalization for a
lumbar puncture and muscle biopsy (under general anes-
thesia), he never regained the ability to walk, due to
increased dystonia and muscle weakness in the legs. At the
last examination, at 6.5 years old, he had moderate-to-
severe generalized dystonia (Burke–Fahn–Marsden Dysto-
nia Rating Scale [BFMS] score = 80.5, disability score = 23/
30; see Supplementary Video S6), dysarthria, and dyspha-
gia, and was completely dependent on his parents. He also
complained of painful spasms in his left limbs, occurring
when he moved or during sleep. He communicated with
short sentences, but was difficult to understand. Cognitive
assessments revealed a moderate/severe language delay and
mild cognitive impairment. There was also moderate axial
hypotonia and spasticity in the lower extremities, general-
ized hyperreflexia, ankle clonus, and bilateral Babinski
signs. Cranial nerve examination shows saccadic pursuits
and mild tremor of the tongue. There was proximal mus-
cle weakness, more severe in the legs (3/5, with decreased
muscle mass) than the arms (4/5). Different oral medica-
tions were tried (see Table 2), with only mild or no bene-
fit for the dystonia. Extensive diagnostic workup was
initially unremarkable. Brain MRI showed abnormal, non-
enhancing, focal, symmetric T2-hyperintense,
T1-hypointense abnormalities at the bulbomedullary junc-
tion (Fig 2A–C). MRI of the spine was unremarkable. A
cerebral positron emission tomography (PET) scan rev-
ealed a mild global decrease in cerebral activity, particu-
larly in the basal ganglia.
The Israeli patient (D-II-1) was born at term, fol-
lowing normal pregnancy and delivery, and had normal
physical and cognitive development. He started walking at
the age of 13 months, with abnormal posturing of the
right leg during walking and recurrent falls. The dystonia
gradually spread to both legs and then the arms, more
FIGURE 2: Neuroimaging. (A–C) Brain magnetic resonance imaging (MRI; T2-axial view) in Patient C-II-1 (de novo p.Gly130Arg
variant), showing abnormal, focal concentric, symmetric hyperintense signal abnormalities in the posterior brain stem at the
bulbomedullary junction. (D, E) Fluid attenuated inversion recovery (FLAIR) MRI images (axial view) in Patient E-II-3 (p.Asn32Thr
variant), showing bilateral frontal–parietal atrophy and mild hyperintense signal in the posterior periventricular white matter.
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prominent on the right side, with no diurnal variation. An
L-dopa trial was discontinued due to gastrointestinal side
effects and possible aggravation of the dystonia. At the age
of 18 years, he had walking difficulties and could not use
his right arm. Neurologic examination showed dystonic
postures of the right arm and both legs during walking
(BFMS score = 53), normal muscle strength, dystonic
tremor in the hands, brisk reflexes, bilateral ankle clonus,
bilateral Babinski sign, and pes cavus. Laboratory workup
was unremarkable, apart from low serum ceruloplasmin
FIGURE 3: Expression studies. Dystonia-associated EIF2AK2 variants lead to prolonged phosphorylation of EIF2AK2 Thr446 and
downstream target eIF2α-Ser51 in patient-derived fibroblasts in response to polyinosinic acid:polycytidylic acid (poly[I:C])
exposure. (A) Schematic representation of the EIF2AK2 protein structure double-stranded RNA binding motif (DRBM). Locations
of the variants detected in the patients are indicated. (B) Schematic diagram showing the downstream effectors of the EIF2AK2
pathway after treatment with poly(I:C). (C) Representative Western blots of protein extracts from control (Control 1, 2, 3) and
EIF2AK2 patient (E-II-3, B-II-1, A-III-4) fibroblast cell cultures that were either untreated or treated with poly(I:C) (2μg/ml) for
16 hours. Protein extracts were probed on the same blot for expression of phosphorylated EIF2AK2 (EIF2AK2 P-Thr446), total
EIF2AK2 protein levels (EIF2AK2), phosphorylated eIF2α (eIF2α P-Ser51), and total eIF2α (eIF2α) protein levels. Vinculin was
used as protein loading control. Molecular weights are indicated on the left (kDa). (D) Quantification of total EIF2AK2 levels in
untreated cell cultures showing no significant changes between control and patient fibroblast cell cultures (n = 5). (E)
Quantification of phosphorylated Ser51 eIF2α protein levels in untreated cell cultures, indicating no changes in EIF2AK2 variant
carrying patient cells compared to unrelated control fibroblasts (n = 5). (F) Quantification of the fold change of phosphorylated
EIF2AK2 Thr446 over total EIF2AK2 protein levels after poly(I:C) treatment (2μg/ml) for 16 hours normalized to untreated cells.
(G) Quantification of the fold change of phosphorylated eIF2αSer51 over total eIF2α protein levels after poly(I:C) treatment
(2μg/ml) for 16 hours normalized to untreated cells. Two-way analysis of variance with Tukey multiple comparisons between
controls and subjects with EIF2AK2 variants were performed. Values represent mean ± standard error of the mean (n = 3
biological replicates; ****p < 0.0001). [Color figure can be viewed at www.annalsofneurology.org]
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(16mg/dl, normal range = 20–60) and increased urinary
copper, in the absence of a Kayser–Fleischer ring, and
with an unremarkable liver biopsy. Electromyography/
nerve conduction velocity (EMG/NCV) revealed no evi-
dence of polyneuropathy. Brain MRI at the age of
14 years was reported as normal, but hyperintense foci
were noted in the left-frontal white matter (unfortunately,
images are not available). His 61-year-old mother, known
for diabetes mellitus type II and hyperlipidemia, com-
plained of infrequent, transient muscle cramps and numb-
ness of the fingertips, lasting several seconds. Her
neurologic examination revealed no neurologic deficits,
apart from a minimal postural tremor of the hands.
The Italian patient (E-II-3, Family E; see Fig 1E)
was born full term after an uncomplicated pregnancy;
motor milestones as well as speech were delayed, with
independent ambulation at age 3 years, with clumsiness.
Generalized tonic epileptic seizures occurred in the first
months of life, but were well controlled on antiepileptic
drugs. This medication was discontinued at age 3 years,
with no recurrence of seizures. The patient also has intel-
lectual disability. At age 5 years, after a febrile illness with
high temperature, he developed a slowly progressive gener-
alized dystonia, with a prominent axial component, more
severe in the trunk and neck (severe retrocollis). He lost
the ability to walk independently in adulthood, and spas-
tic paraparesis developed around age 30 years. Currently,
the patient is aged 42 years and his clinical picture is char-
acterized by generalized dystonia with severe axial involve-
ment (BFMS score = 84), spastic paraparesis with bilateral
Babinski signs, intellectual disability, spastic/dystonic dys-
arthria, mild dysphagia, and reduced vertical up-gaze.
Brain MRI at age 30 and 40 years displayed frontal–
parietal atrophy and mild hyperintensity in the posterior
periventricular white matter on T2-weighted images (see
Fig 2D, E). Oral drugs (L-dopa, trihexyphenidyl, baclo-
fen, clonazepam) as well as botulinum toxin injections
(neck) were marginally beneficial to alleviate dystonia.
Expression Studies
To investigate the effect of the identified EIF2AK2 vari-
ants on EIF2AK2 protein function, we analyzed endoge-
nous protein expression levels and phosphorylation status
of the EIF2AK2 protein itself, as well as a well-known
downstream target of EIF2AK2 kinase activity, the eIF2α
protein, in human skin fibroblast cultures from 3 patients
with different EIF2AK2 variants (2 with the heterozygous
p.Gly130Arg variant [B-II-1, A-III-4], 1 with homozygous
p.Asn32Thr variant [E-II-3]), and 3 unrelated unaffected
controls (Fig 3A). We compared the expression levels at
steady state (unstimulated cells) as well as in cultures after
the EIF2AK2–eIF2α pathway was activated via treatment
with the dsRNA molecule poly(I:C) HMW by transfec-
tion via Viromer Red compound. This method was cho-
sen to mimic as close as possible the canonical activation
of the EIF2AK2-eIF2α pathway by viral dsRNA, as
EIF2AK2 plays a central role in mediating antiviral
responses (see Fig 3B, C).23 Total and Thr446 phosphory-
lated EIF2AK2, as well as total and Ser51 phosphorylated
eIF2α were unchanged at steady state (unstimulated) com-
paring fibroblasts derived from patients with EIF2AK2
missense variants and unaffected individuals (see Fig 3D,
E). Treatment with poly(I:C) HMW elicited a robust acti-
vation of the pathway in all cell lines, without significant
differences between patients and controls at 4 or 8 hours
after treatment (data not shown). Remarkably, after
16 hours, both phosphorylated Thr446 EIF2AK2 and
Ser51 eIF2α levels were significantly elevated in all
EIF2AK2 patient fibroblasts (phosphorylated Thr446
EIF2AK2: average 5.4 fold ± 1.2 standard deviation [SD];
Ser51 eIF2α: average 3.1 fold ± 0.2 SD) when compared
FIGURE 4: Evidence for dysregulated eIF2α signaling as a
shared theme in the pathogenesis of dystonia. Identification
of EIF2AK2 variants in this study provides further support for
dysregulated eIF2α signaling as a shared pathogenetic
theme in dystonia. Evidence for a disturbed integrated stress
response (ISR) has been previously reported in other
monogenic causes of dystonia, including DYT-PRKRA, DYT-
TOR1A, DYT-THAP1, and DYT-SGCE. Several studies have
shown that variants in the PRKRA gene enhanced the
susceptibility to endoplasmic reticulum stress leading to
heightened EIF2AK2 activation, dysregulation of ISR, and
increased apoptosis.32,34,35 ISR dysregulation has been
reported to play a central role in DYT-TOR1A.10,11,36 THAP1
mutations have been shown to cause dysregulation of the
eIF2α signaling pathways in a DYT-THAP1 mouse model.12 In
a mouse model of DYT-SGCE, significantly elevated levels of
EIF2AK2 transcript are reported, and genes associated with
protein translation are among the top downregulated
mRNAs.37 Additionally, rare variants in ATF4—a direct target
of eIF2α signaling—have also been reported in cervical
dystonia patients.11 [Color figure can be viewed at www.
annalsofneurology.org]
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to unaffected control cell lines (phosphorylated Thr446
EIF2AK2: average 0.8 fold ± 0.05 SD; Ser51 eIF2α: aver-
age 1.6 fold ± 0.1 SD). These results show that the activa-
tion of both EIF2AK2 and eIF2α persists for a longer
duration in patient-derived fibroblasts compared to unaf-
fected control cells.
Discussion
Here we report the identification of 3 different EIF2AK2
missense variants, absent from gnomAD and other public
databases, that are present in 9 patients from 5 unrelated
families with early onset, generalized dystonia. We also
show abnormally increased activation of the EIF2AK2
pathway in cell lines from patients carrying 2 of these
variants.
The evidence for a causative role in disease develop-
ment is strong for the c.388G>A, p.Gly130Arg variant,
which was prioritized as a result of a genome-wide unbi-
ased search and segregates with the disease in all patients
in the Taiwanese family, as well as being present in
2 unrelated patients of Caucasian ethnicity with very simi-
lar or identical phenotypes. Remarkably, in one of these
patients the variant occurred de novo. According to the
American College of Medical Genetics and Genomics
(ACMG) guidelines for interpretation of genetic variants
in the clinical setting,24 the p.Gly130Arg variant would be
classified as pathogenic, and the p.Asn32Thr variant as
likely pathogenic. The evidence for pathogenicity of the
third variant (p.Gly138Ala) remains inconclusive
according to these criteria, pending its identification in
other patients or functional studies.
It is noteworthy that the p.Gly130Arg variant segre-
gated with disease in heterozygous state in the Taiwanese
family, and occurred de novo in the Canadian patient,
according to a dominant mechanism of action. Instead,
the p.Asn32Thr variant was present in homozygous state
in the Italian patient, while heterozygous in his unaffected
parents (recessive inheritance). Different modes of inheri-
tance have been reported for other genes causing dystonia
(such as DYT-THAP1 and DYT-GNAL)2 or other move-
ment disorders (PDE10A and ADCY5).25
Of note, the EIF2AK2 variants identified in this
study and those reported in the previous publication13 are
not predicted to be functionally damaging by the majority
of in silico prediction algorithms.17 This phenomenon
appears to be largely due to the lack of evolutionary con-
servation of the EIF2AK2 protein sequence.26,27 Likewise,
the recurrent p.Pro222Leu missense variant in the
PRKRA protein, established as the cause of DYT-PRKRA,
also alters a residue that lacks evolutionary conservation,
and that variant is also predicted to be benign by most in
silico tools. PRKRA is a functional interactor of PKR, the
protein product of EIF2AK2. The phenotype of DYT-
PRKRA and that of EIF2AK2, as we report it here, are
also remarkably similar (early onset generalized dystonia,
often without additional neurological manifestations). It is
therefore tempting to speculate that the PRKRA/EIF2AK2
pathway has acquired special functions in the recent evo-
lution of primates. In keeping with this hypothesis, the
EIF2AK2 gene does not display any common coding vari-
ants in humans. The most common missense variant
(c.575C>G p.Ser192Cys) has an MAF of only
0.000177j50/282502j0.0177% in gnomAD v2.1. These
observations collectively suggest an important, human-
specific function of this protein. Independent lines of
research have shown that the EIF2AK2 protein is under
evolutionary pressure compared to other branches of this
family of protein kinases.27 The accelerated evolution and
species-specificity appear both to be related to the involve-
ment of this protein in the cellular response to viral infec-
tions and its coevolution with the infecting viruses.27
Our functional studies show that EIF2AK2 variants
identified in patients with dystonia lead to abnormally
persistent activation of the EIF2AK2–eIF2α pathway,
whose main function as part of the ISR is inhibition of
protein synthesis, and induction of programmed cell death
as a first line of defense against numerous types of cellular
stress.28 For efficient recovery and cellular survival after
cellular stress, it is also essential that the temporary inhibi-
tion of protein synthesis caused by phosphorylated eIF2α
is promptly reversed, aided by protein phosphatase 1 com-
plex, leading to synthesis of survival-related proteins at
later time points.3 As depicted in Figure 3, the activation
of EIF2AK2, and eIF2α phosphorylation are abnormally
protracted in the patient-derived fibroblasts as compared
to control cells after dsRNA treatment. This might lead to
permanent cell abnormalities, as recovery and survival
mechanisms may not be induced efficiently in these sub-
jects. Identification of EIF2AK2 variants in our study pro-
vides further support for dysregulated eIF2α signaling as a
shared pathogenetic theme in dystonia. Previously, other
monogenetic causes of dystonia have been identified
where the ISR is disturbed (Fig 4).
Intriguingly, eIF2α phosphorylation and down-
stream effectors have also been linked to synaptic
plasticity,29 a pathway that might have important roles in
the development of dystonia.2 However, whether abnor-
malities in these or other functions of eIF2α signaling are
involved in the pathogenesis of dystonia in the patients
with EIF2AK2 variants remains to be determined.
All 3 missense variants identified in this study are
localized in either the first or second dsRNA binding
motif (DRBM) of EIF2AK2 (see Fig 1H). These variants
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might lead to disturbed dsRNA binding kinetics of the
DRBMs, resulting in the extended activation of EIF2AK2
and of the ISR. Alternatively, DRBM1 and DRBM2 are
also required for the interaction with the C-terminal
DRBMs of the PRKRA protein.8,31 The variants identi-
fied in the dystonia patients might therefore influence the
binding kinetics of EIF2AK2 to PRKRA, also resulting in
the prolonged activation of the ISR. This would be in line
with a previous study showing that in patient-derived cells
carrying the PRKRA dystonia-causing p.Pro222Leu vari-
ant, the affinity of PRKRA–EIF2AK2 interactions is
enhanced, thereby leading to intensified EIF2AK2 activa-
tion and enhanced cellular death.32
In the patients described here, the clinical phenotype
associated with EIF2AK2 variants appears broad, even in
the carriers of the same variant. Childhood onset, severe
generalized dystonia was the shared, prominent feature in
9 of our cases. In 6 of these 9, the dystonia remained iso-
lated, without additional neurological manifestations,
whereas the other 3 also developed mild intellectual dis-
ability, spasticity, and brain MRI alterations. Severe axial
involvement was noted in 7 of these 9 cases, being a
potential clinical clue. Such a wide clinical spectrum is not
surprising, given that other genes causing early onset dys-
tonia are associated with a phenotypic continuum, ranging
from pure dystonia to more complex presentations.2,33
Moreover, our observations suggest an incomplete pene-
trance and variable expressivity for EIF2AK2 variants, as
also frequently reported for variants causing other autoso-
mal dominant forms of dystonia, including DYT-TOR1A
and DYT-THAP1.1,2 Among the subjects who carried the
EIF2AK2 p.Gly130Arg variant, one (B-I-1) remained
asymptomatic and free from dystonic signs or neurological
symptoms at examination at the age of 41 years; another
(A-II-2, 51 years of age) only reported symptoms compati-
ble with foot dystonia in childhood, whereas a third
(A-1-2, 60 years of age) developed only a segmental form
of dystonia (see Table 2). Another subject (D-I-2, p.
Gly138Ala variant) reported cramps in her hands, and the
neurologic examination only revealed a minimal bilateral
postural tremor of the hands.
Recently, de novo missense variants in EIF2AK2
have independently been reported as the cause of a com-
plex neurodevelopmental syndrome that appears to share
phenotypic and pathogenic mechanisms with central ner-
vous system hypomyelination/vanishing white matter dis-
ease.13 In 8 patients reported with EIF2AK2 de novo
missense variants, the phenotype was dominated by devel-
opmental delay, language and cognitive impairment, and
white matter alterations. Ataxia, dysarthria, hypotonia,
parkinsonism, and seizures were also present in some of
them, and dystonia (additional details were not provided)
was mentioned in 5 cases.13 All those 8 patients exhibited
neurological regression in the setting of febrile illness or
infection. This phenotype appears to overlap marginally
with that displayed by only some of our cases. Onset of
dystonia or deterioration in the context of febrile illness or
general anesthesia was also noted in 2 of our patients, and
may represent a diagnostic clue to suspect EIF2AK2 muta-
tions in patients with early onset dystonia.
In the same report, it was shown that the EIF2AK2
missense variants encode stable proteins, and the kinase
activity of EIF2AK2 is reduced after poly(I:C) treatment
in mammalian cell lines and proband-derived fibroblasts.13
Although the unaffected stability of the missense
EIF2AK2 variants in unstressed cells is in line with our
findings, we did not observe reduced kinase activity after
poly(I:C) treatment. There may be several explanations for
these discrepancies, such as different methodologies, or
different EIF2AK2 variants might lead to different func-
tional and clinical outcomes. The variants reported in the
previous study and those reported here are not localized at
the same amino acid positions, with one exception: at
amino acid position 32, the previous study reports an
asparagine to serine substitution, whereas in our patient
that asparagine is changed into threonine.
One limitation of our study is that, although func-
tional experiments have been performed using endogenous
protein expression in patient-derived fibroblasts, the dis-
ease affects brain cells. Although the ISR is ubiquitously
present in all organs, we cannot exclude brain tissue- or
cell-specific responses that would have been missed in the
current study.
Finally, our findings have potential clinical implica-
tions for the patients carrying EIF2AK2 variants. First, as
EIF2AK2 appears to be hyperactivated in response to cel-
lular stress signals such as viral infections, and neurological
deterioration is reported in the context of febrile illness,
infections, and general anesthesia, it seems arguable for
the patients to limit exposure to viruses and other infective
agents, and to conditions of severe metabolic stress. More-
over, development of therapies focused on inhibiting the
EIF2AK2 kinase activity as a treatment of dystonia
patients carrying the reported variants should be explored.
Our data also suggest that caution is warranted when
assessing pathogenicity of variants based on DNA or pro-
tein sequence conservation, for human genes and path-
ways under selective evolutionary pressure.
In conclusion, we identify rare EIF2AK2 variants
implicated in early onset generalized dystonia, which
might be dominantly or recessively inherited, or occur de
novo. Our findings provide direct evidence for a key role
of a dysfunctional eIF2α pathway in the pathogenesis of
dystonia.
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